Business Context and Reporting Period
Company: electroCore, Inc. (ECOR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: electroCore is a bioelectronic technology company focused on non-invasive devices for primary headache (gammaCore), fibromyalgia (Quell), and general wellness/human performance (Truvaga, TAC-STIM). The company operates as a single segment: Bioelectronic Innovations.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Sales | $32.0 million | $25.2 million |
| Gross Profit | $27.8 million | $21.4 million |
| Gross Margin | 87% | 85% |
| Net Loss | $(14.0) million | $(11.9) million |
| Operating Loss | $(13.2) million | $(12.2) million |
| Cash & Equivalents (Year End) | $7.0 million | $3.7 million |
| Total Cash, Equivalents & Marketable Securities | $11.6 million | $12.2 million |
| Long-Term Debt | $6.6 million (net) | $0 |
| Stockholders' Equity (Deficit) | $(1.7) million | $7.5 million |
Liquidity: The company reported a net loss of $14.0 million and used $8.2 million in cash from operating activities. As of December 31, 2025, total cash, cash equivalents, and marketable securities totaled $11.6 million. Management has raised substantial doubt regarding the company's ability to continue as a going concern, noting that forecasted cash is insufficient to fund operating expenses for the next 12 months without additional financing.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 27% to $32.0 million, driven by a 25% increase in U.S. prescription sales (primarily to the VA) and a 97% increase in General Wellness sales (Truvaga).
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 22% to $38.2 million, driven by a $4.3 million increase in sales and marketing (including $3.8 million in variable expenses) and higher legal fees ($0.8 million) and bad debt expense ($0.5 million).
- Debt Financing: In August 2025, the company entered a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., securing $7.5 million in term loans (Tranche 1). This resulted in a new long-term debt balance of $6.6 million (net of discounts) and increased interest expense.
- Acquisition: Completed the acquisition of NeuroMetrix, Inc. (NURO) in May 2025, adding the Quell Fibromyalgia platform to the product portfolio.
- Customer Concentration: The U.S. Department of Veterans Affairs (VA) accounted for 71.2% of total revenue in 2025, up slightly from 70.6% in 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The company explicitly states that its current cash position is insufficient to fund operations for the next 12 months. It plans to raise additional capital through equity or debt offerings, but there is no assurance such funds will be available on acceptable terms.
- Management Transition: CEO Daniel S. Goldberger notified the company of his intention to retire effective April 1, 2026. CFO Joshua S. Lev will serve as Interim President. A new Chief Operating Officer, Michael Fox, was hired effective April 17, 2026.
- Internal Control Weakness: The company identified a material weakness in internal control over financial reporting related to lease accounting. Disclosure controls were deemed ineffective as of December 31, 2025. Remediation efforts are underway.
- Legal Proceedings: The company is engaged in patent litigation with UAB Pulsetto regarding non-invasive vagus nerve stimulation technology. The outcome is uncertain and could result in significant costs or judgments.
- Regulatory & Market Risks: Risks include potential delisting from Nasdaq due to stockholders' equity falling below $2.5 million, dependence on government funding (VA/NHS), and the need to demonstrate market acceptance for new products like gammaCore Emerald and Quell Fibromyalgia.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure additional financing given the "substantial doubt" regarding going concern status and the $11.6 million cash balance against a $14.0 million annual burn rate.
- Customer Concentration: Assess the risk associated with 71.2% of revenue coming from the U.S. Department of Veterans Affairs and the impact of potential government budget cuts or shutdowns.
- Debt Covenants: Review the terms of the Avenue Loan and Security Agreement, specifically the financial covenants (minimum revenue and cash levels) and the risk of default.
- Internal Controls: Monitor the remediation of the material weakness in lease accounting and the effectiveness of disclosure controls in future filings.
- Product Adoption: Track the commercial performance of the newly acquired Quell Fibromyalgia platform and the gammaCore Emerald device to determine if they can offset the high operating costs.